• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks
    1. Home>
    2. Life Science Investing News>
    Loading...
    0

    Sci-Fi Meets Reality: Lab-Grown Organs, Woolly Mice and 3D-Printed Hearts Redefining Life Sciences

    Meagen Seatter
    Mar. 10, 2025 01:15PM PST

    Companies in the life science sector are embracing new technology to make advances in diverse industries, from organ development to de-extinction.

    Pink DNA strands.
    tolem929 / Adobe Stock

    The line between science fiction and reality is blurring at an astonishing pace, as evidenced by groundbreaking research from the University of California San Francisco and Cedars-Sinai.

    Scientists there have recently developed a method for directing stem cells to form specific organ-like structures, essentially creating a “blueprint” for organ development. By engineering “organizer cells” that act as instructors, they can coax stem cells to form rudimentary organs, including a heart structure that beats and has a ventricle-like cavity.

    While this research is nascent, it is one example of the remarkable advancements that once seemed confined to the realms of fantasy happening in the life science sector.


    From growing organs in a lab to transplanting animal organs into humans, science continues to push the boundaries of what's possible, offering a glimpse into a revolutionary future.

    1. Colossal Bioscience

    — (@)

    On March 4, Time Magazine covered the company’s groundbreaking achievement: using gene editing tools, Colossal managed to breed “woolly mice” with woolly mammoth characteristics, specifically long, thick coats of fur and accelerated fat metabolism.

    Scientists were able to reconstruct the woolly mammoth genome by harvesting DNA from multiple samples taken from Alaska and Siberia. They then compared the genome to that of the Asian elephant, the closest living relative of woolly mammoths, to identify the specific genetic differences that made mammoths unique.

    Researchers then used CRISPR-Cas9 to make specific changes to the genome of mouse embryos, giving them traits similar to those of the woolly mammoth. The result was the world’s first “woolly mice”.

    “The Colossal woolly mouse marks a watershed moment in our de-extinction mission,” said company CEO Ben Lamm in a statement. “By engineering multiple cold-tolerant traits from mammoth evolutionary pathways into a living model species, we've proven our ability to recreate complex genetic combinations that took nature millions of years to create.”

    The company’s CEO, Ben Lamm, says the ecological effects caused by the threat of extinction will eventually lead to economic impacts, citing an estimate from the World Economic Forum that predicts biodiversity loss could cause the global GDP to lose US$2.7 trillion annually by 2030.

    In a 2022 interview with Christine Lagorio-Chafkin for the What I Know podcast, Lamm explained that a higher population of large herbivores could reduce ground surface temperatures, decelerating the thaw of arctic permafrost that some studies project will release between 119.3 and 251.6 billion tons of carbon by 2100.

    To support its goals, the company raised US$200 million in January from TWG Global in a Series C funding round, bringing its total cash raised to US$435 million and its total valuation to US$10.2 billion.

    The company is also researching ways to resurrect the Tasmanian tiger and the dodo bird.

    2. Loyal

    On February 26, the US Food and Drug Administration (FDA) accepted the Reasonable Expectation of Effectiveness section of Loyal's conditional approval application for LOY-002, a daily tablet developed by the company to extend the lifespan for dogs aged 10 and older weighing at least 14 pounds. The pill targets metabolic dysfunction and provides an alternative to caloric restriction and other established longevity interventions.

    In a May 2022 interview published in Authority Magazine, Celine Halioua, the company’s CEO, explained the objective of a cross-sectional epigenetic study, X-Thousand Dogs. “In addition to sequencing a dog’s DNA, the X-Thousand Dogs study is looking for changes in the structure of the DNA itself," she explained at the time. “By identifying and tracking these changes, Loyal can create a snapshot into what is happening with a dog’s health.”

    Halioua said she hopes that Loyal’s research will have future human applications. “The company’s thesis is that research and therapeutics for extending healthspan and lifespan for dogs will lead to further understanding of aging in humans.”

    To support its submission to the FDA, the company is currently running the STAY study, a four year, double-blind placebo clinical trial that began in December 2023. Loyal also recently secured US$22 million in a Series B-2 funding round led by Valor Equity Partners, a private equity firm that has also invested in SpaceX, Neuralink, Anduril and The Boring Company.

    3. United Therapeutics (NASDAQ:UTHR)

    Company Profile

    3D bioprinting, a US$2 billion industry with an estimated compound annual growth of 12.5 percent by 2030, is tackling the organ donor shortage with innovative tissue engineering solutions. In August 2024, a team of scientists at the Harvard John A. Paulson School of Engineering and Applied Sciences and Wyss Institute for Biologically Inspired Engineering developed a new 3D printing technique to create realistic blood vessel networks within human heart tissue.

    These networks closely resemble natural blood vessels, featuring a muscle and cell shell around a fluid-carrying core.

    “In prior work, we developed a new 3D bioprinting method, known as ‘sacrificial writing in functional tissue’ (SWIFT), for patterning hollow channels within a living cellular matrix," first author Paul Stankey, a bioengineering PhD student, told Lindsay Brownell in a piece written for the Wyss Institute for Biologically Inspired Engineering.

    "Here, building on this method, we introduce coaxial SWIFT (co-SWIFT) that recapitulates the multilayer architecture found in native blood vessels, making it easier to form an interconnected endothelium and more robust to withstand the internal pressure of blood flow,” Stankey continued on to explain.

    United Therapeutics is one company involved in this work. In 2022, scientists at the company engineered a 3D-printed human lung scaffold in collaboration with 3D Systems. The scaffold was complete with 4,000 kilometers of capillaries and 200 million alveoli capable of oxygen exchange in animal models. The goal was to cellularize scaffolds with patients’ stem cells to create functional lungs for transplant without the risk of rejection. “

    With the continued hard work of dedicated scientists and engineers at United Therapeutics and 3D Systems, we hope to have these personalized, manufactured lungs cleared for human trials in under five years,” Dr. Martine Rothblatt, United Therapeutics’ xhairperson and CEO, said in a press release at the time.

    Researchers are also exploring the possibilities of xenotransplantation — the transplanting of organs from one species to another — to address the organ donor shortage.

    United Therapeutics has made progress in this area as well, performing successful transplants of its “U-organs” (genetically modified pig organs), including two UHeart transplants, a combined kidney/thymus transplant and a UKidney transplant under compassionate use exemptions between 2022 and 2024. In February 2025, the company received FDA clearance to begin a formal clinical trial of its UKidney.

    4. eGenesis

    eGenesis is also making significant progress in xenotransplantation through its collaborations with Massachusetts General Hospital (MGH). In March 2024, surgeons at MGH successfully transplanted a genetically engineered pig kidney into a living human patient in a procedure authorized by the FDA under the Expanded Access pathway.

    eGenesis then received US$191 million in September 2024 to advance its kidney, code-named EGEN-2784, to in-human studies. In a statement emailed to Nature, the company said it received FDA approval to conduct three pig kidney transplants under compassionate use in December 2024.

    A second patient — the first in this study — with end-stage renal disease received the operation on January 25 of this year. The patient was discharged in good health a week after the surgery and is no longer receiving dialysis.

    Beyond its pig kidney research, eGenesis has also begun collaborating with OrganOx, a commercial-stage organ technology company spun out of the University of Oxford in 2008. Their work involves developing a liver support system that uses genetically modified pig livers in OrganOx's metra device, a normothermic machine perfusion system, to temporarily perform liver functions for patients with acute liver failure.

    Don’t forget to follow @INN_LifeScience for real-time updates!

    Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

    From Your Site Articles
    • 5 US Longevity and Anti-aging Stocks to Watch in 2025 ›
    • Top 5 Life Science ETFs in 2024 ›
    • 2025 Life Science Outlook Report ›
    Related Articles Around the Web
    • A Recovery for All of Us: New York City Invests $1 Billion in Life ... ›
    • Governor Healey Highlights Life Sciences Investments from Mass ... ›
    https://twitter.com/INN_Technology
    https://www.linkedin.com/in/meagen-seatter-23675b193/
    mseatter@investingnews.com
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Meagen Seatter

    Meagen Seatter

    Investment Market Content Specialist

    Meagen moved to Vancouver in 2019 after splitting her time between Australia and Southeast Asia for three years. She worked simultaneously as a freelancer and childcare provider before landing her role as an Investment Market Content Specialist at the Investing News Network.

    Meagen has studied marketing, developmental and cognitive psychology and anthropology, and honed her craft of writing at Langara College. She is currently pursuing a degree in psychology and linguistics. Meagen loves writing about the life science, cannabis, tech and psychedelics markets. In her free time, she enjoys gardening, cooking, traveling, doing anything outdoors and reading.

    Latest News

    Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Life Science Investing News Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×
    Meagen Seatter
    Meagen Seatter

    Investment Market Content Specialist

    Meagen moved to Vancouver in 2019 after splitting her time between Australia and Southeast Asia for three years. She worked simultaneously as a freelancer and childcare provider before landing her role as an Investment Market Content Specialist at the Investing News Network.

    Meagen has studied marketing, developmental and cognitive psychology and anthropology, and honed her craft of writing at Langara College. She is currently pursuing a degree in psychology and linguistics. Meagen loves writing about the life science, cannabis, tech and psychedelics markets. In her free time, she enjoys gardening, cooking, traveling, doing anything outdoors and reading.

    Full Bio

    Follow

    Learn about our editorial policies.